Rani Therapeutics Holdings, INC DEF 14A proxy statements

Rani Therapeutics Holdings, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders to be held virtually on May 28, 2026.

Rani Therapeutics Holdings, Inc. completed a $60.3 million private placement and approved significant corporate governance changes, including reducing Class B voting power and eliminating stockholder written consent, to address financial needs and comply with Nasdaq rules.

Rani Therapeutics Holdings, Inc. announced a private placement transaction where an existing institutional investor exercised warrants at a reduced price, providing $4.3 million in gross proceeds, and received new warrants, with the issuance of underlying shares approved by a majority stockholder to address capital needs and going concern doubt.

Laureen DeBuono has withdrawn her nomination for reelection to the Board of Directors of Rani Therapeutics, effective immediately.

Rani Therapeutics Holdings, Inc. has filed a definitive proxy statement with the SEC.

Rani Therapeutics has announced its annual meeting of stockholders to be held virtually on May 28, 2025, to vote on the election of directors and ratification of the company's independent auditor.

Rani Therapeutics Holdings, Inc. has filed a definitive proxy statement with the SEC.

Rani Therapeutics Holdings, Inc. will hold its Annual Meeting of Stockholders virtually on May 29, 2024, to elect directors and ratify the selection of Ernst & Young LLP as the independent registered public accounting firm.